To date, we have received 1191 responses (patient and caregiver surveys combined) to the 2020 Global Patient Survey on Lymphomas & CLL! Great job everyone! Keep reading to the end of this email for more information on marketing the survey, including information on what has been translated for your use.
See below for the survey count by member countries for patient respondents:
The highlighted countries have surpassed 100 respondents, and will receive a country report.
We have also tracked the survey completion counts by subtype from patient respondents:
|Anaplastic large cell||7|
|Extranodal Killer T-cell||0|
The highlighted subtypes have surpassed 100 respondents, and will have a subtype report.
Thank you to everyone who has already shared the 2020 Global Patient Survey. A big thank you to Belgium and India for your increased marketing of the survey this year, as we definitely see increased participation from these countries to date. For those that have not done so, please share the link with your membership, healthcare community and social media.
The marketing materials have now been added to the members side of the LC website. The materials have all been translated into the same 19 languages that the survey is offered in. CLICK HERE to access them. Your login is required. If you need help with your username and password, please contact marketing@lymphomacoalition.
Here's what you can do to help us reach our goal:
- Host the information on your website.
- Send an email to your membership, sponsors and other partners encouraging them to take the survey and pass the message along.
- Share with your followers on social media.
- Here is the link to the survey from the LC website
- Here is the link directly to the survey (if you share this link, the survey will automatically show in the language that the respondent’s internet browser uses if it is one of the translated languages).
All your efforts to help promote participation in the 2020 Global Patient Survey are greatly appreciated.
Reminder - countries with 100+ respondents (from patients) will receive a specialised by country report.
Together, we will ensure patients are given the opportunity to share feedback about their experience and help shape the global lymphoma landscape.